UPDATE: The Avastin Argument

Premium

UPDATE: An FDA advisory panel has once again voted to remove the breast cancer indication from Avastin's label, unconvinced by evidence presented by Roche that claims certain breast cancer patients respond very well to the drug. Despite FDA's decision, Roche subsidiary Genentech says it will move forward with plans to study a certain group of breast cancer patients with high levels of VEGF-A that the company calls "super responders," as they respond to Avastin very well.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.